Elevar Therapeutics
Seong Jang currently serves as the Chief Operating Officer at Elevar Therapeutics since March 2022. Prior to this role, Seong Jang worked at the FDA from September 2002 to February 2022, holding the position of Lead Pharmacologist in the Division of Infectious Disease Pharmacology within the Office of Clinical Pharmacology. Additionally, Seong Jang was a Reviewer in the Division of Clinical Pharmacology 4, also under the Office of Clinical Pharmacology at the FDA.
This person is not in any offices
Elevar Therapeutics
Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with thepotential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.Elevar Therapeutics holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.